Flosequinan (BioDeep_00000179093)

   

human metabolite blood metabolite


代谢物信息卡片


7-Fluoro-3-methanesulphinyl-1-methyl-1,4-dihydroquinolin-4-one

化学式: C11H10FNO2S (239.04162520000003)
中文名称: 氟司喹南
谱图信息: 最多检出来源 Homo sapiens(blood) 80%

分子结构信息

SMILES: CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C
InChI: InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3

描述信息

C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases > C01DB - Quinolone vasodilators
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

同义名列表

5 个代谢物同义名

7-Fluoro-3-methanesulphinyl-1-methyl-1,4-dihydroquinolin-4-one; 7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one; 7-Fluoro-1-methyl-3-methylsulfinyl-4-quinoline; flosequinan; manoplax



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • J L Rouleau, B Pitt, N S Dhalla, K S Dhalla, K Swedberg, M S Hansen, E Stanton, N Lapointe, M Packer. Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. American heart journal. 2003 May; 145(5):926-32. doi: 10.1016/s0002-8703(02)94782-4. [PMID: 12766756]
  • G W Moe, J L Rouleau, L Charbonneau, G Proulx, J M Arnold, C Hall, J de Champlain, A Barr, P Sirois, M Packer. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. American heart journal. 2000 Apr; 139(4):587-95. doi: 10.1016/s0002-8703(00)90035-8. [PMID: 10740139]
  • J K Lindsey, J Wang, B Jones, W D Byrom, I D Hind. Simultaneous modelling of flosequinan and its metabolite. European journal of clinical pharmacology. 2000 Feb; 55(11-12):827-36. doi: 10.1007/s002280050704. [PMID: 10805061]
  • E Kashiyama, T Yokoi, M Odomi, T Kamataki. Stereoselective S-oxidation and reduction of flosequinan in rat. Xenobiotica; the fate of foreign compounds in biological systems. 1999 Aug; 29(8):815-26. doi: 10.1080/004982599238263. [PMID: 10553722]
  • R Isnard, P Lechat, F Pousset, A Carayon, H Kalotka, H Chikr, J Salloum, D Thomas, M Komajda. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure. Fundamental & clinical pharmacology. 1997; 11(1):83-9. doi: 10.1111/j.1472-8206.1997.tb00173.x. [PMID: 9182081]
  • D P Nicholls, A Droogan, C A Carson, I C Taylor, A P Passmore, G D Johnston, M Kendall, D Dutka, G K Morris, L M Underwood, I D Hind. Pharmacokinetics of flosequinan in patients with heart failure. European journal of clinical pharmacology. 1996; 50(4):289-91. doi: 10.1007/s002280050110. [PMID: 8803521]
  • F Kamali, C Edwards. Possible role of metabolite in flosequinan-related mortality. Clinical pharmacokinetics. 1995 Dec; 29(6):396-403. doi: 10.2165/00003088-199529060-00002. [PMID: 8787946]
  • M C Janssen, P Smits, J Reyenga, T Thien. Acute effects of flosequinan (BTS 49465) in untreated moderate to severe hypertension. Journal of human hypertension. 1995 May; 9(5):363-8. doi: NULL. [PMID: 7623374]
  • G L Bartels, W J Remme, M P Look, D A Kruijssen. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure. Journal of cardiac failure. 1995 Mar; 1(2):117-25. doi: 10.1016/1071-9164(95)90013-6. [PMID: 9420641]
  • E Kashiyama, T Yokoi, T Todaka, M Odomi, T Kamataki. Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan. Biochemical pharmacology. 1994 Jul; 48(2):237-43. doi: 10.1016/0006-2952(94)90093-0. [PMID: 8053920]
  • E Kashiyama, T Todaka, M Odomi, Y Tanokura, D B Johnson, T Yokoi, T Kamataki, T Shimizu. Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat. Xenobiotica; the fate of foreign compounds in biological systems. 1994 Apr; 24(4):369-77. doi: 10.3109/00498259409045900. [PMID: 8059540]
  • J L Hinson, I D Hind, D J Weidler. Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction. Journal of pharmaceutical sciences. 1994 Mar; 83(3):382-5. doi: 10.1002/jps.2600830323. [PMID: 8207686]
  • E Kashiyama, M Odomi, T Shimizu. Stereospecific and simultaneous high-performance liquid chromatographic assay of flosequinan and its metabolites in human plasma. Journal of chromatography. 1994 Feb; 652(2):179-85. doi: 10.1016/0378-4347(93)e0383-2. [PMID: 8006102]
  • D P Dutka, J S Elborn, F Delamere, D J Shale, G K Morris. Tumour necrosis factor alpha in severe congestive cardiac failure. British heart journal. 1993 Aug; 70(2):141-3. doi: 10.1136/hrt.70.2.141. [PMID: 8038024]
  • N Dakak, N Makhoul, A Merdler, H Yechiely, L Kahana, D A Halon, A Schneeweiss, B S Lewis. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. European heart journal. 1993 Jun; 14(6):836-44. doi: 10.1093/eurheartj/14.6.836. [PMID: 8325314]
  • B V Gallo, J L Hinson, D J Weidler. Pharmacokinetic profile of flosequinan in patients with compromised renal function. Journal of pharmaceutical sciences. 1993 Mar; 82(3):282-5. doi: 10.1002/jps.2600820313. [PMID: 8450423]
  • S M Wood, C R Dudley, A M Devaney, C G Winearls. Flosequinan and renovascular disease. Lancet (London, England). 1993 Jan; 341(8837):116-7. doi: 10.1016/0140-6736(93)92595-k. [PMID: 8093384]
  • M Sakai, S Ohkawa, T Kaku, K Kuboki, K Chida, T Imai. Pharmacokinetics of flosequinan in elderly patients with chronic congestive heart failure. European journal of clinical pharmacology. 1993; 44(4):387-9. doi: 10.1007/bf00316479. [PMID: 8513852]
  • P G Cavero, T De Marco, M Kwasman, D Lau, M Liu, K Chatterjee. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. Journal of the American College of Cardiology. 1992 Dec; 20(7):1542-8. doi: 10.1016/0735-1097(92)90448-v. [PMID: 1452928]
  • J Duranteau, E Pussard, A Edouard, K Samii, A Berdeaux, J F Giudicelli. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers. British journal of clinical pharmacology. 1992 Sep; 34(3):207-14. doi: 10.1111/j.1365-2125.1992.tb04126.x. [PMID: 1389945]
  • G Frodsham, R B Jones. Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle. European journal of pharmacology. 1992 Feb; 211(3):383-91. doi: 10.1016/0014-2999(92)90396-l. [PMID: 1319914]
  • H M Lewis, M J Kendall, A D Wright, J R Bratty, S Maxwell. A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus. Journal of clinical pharmacy and therapeutics. 1991 Jun; 16(3):161-6. doi: 10.1111/j.1365-2710.1991.tb00299.x. [PMID: 1869595]
  • D B Yates. Pharmacology of flosequinan. American heart journal. 1991 Mar; 121(3 Pt 1):974-83. doi: 10.1016/0002-8703(91)90229-b. [PMID: 2000776]
  • W J Corin, E S Monrad, J A Strom, S Giustino, E S Sonnenblick, T LeJemtel. Flosequinan: a vasodilator with positive inotropic activity. American heart journal. 1991 Feb; 121(2 Pt 1):537-40. doi: 10.1016/0002-8703(91)90723-u. [PMID: 1990760]
  • H Markus, A J Cowley. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure. European journal of clinical pharmacology. 1991; 40(6):535-8. doi: 10.1007/bf00279964. [PMID: 1884731]
  • G A Riegger, H Kahles, A Wagner, E P Kromer, D Elsner, K Kochsiek. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure. Cardiovascular drugs and therapy. 1990 Oct; 4(5):1395-402. doi: 10.1007/bf02018268. [PMID: 1980598]
  • W P Leary, A J Reyes, R D Wynne, K van der Byl. Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects. The Journal of international medical research. 1990 Mar; 18(2):120-41. doi: 10.1177/030006059001800207. [PMID: 2340945]
  • A Schneeweiss, R D Wynne, A Marmor. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Japanese heart journal. 1989 Sep; 30(5):627-34. doi: 10.1536/ihj.30.627. [PMID: 2614925]
  • A Schneeweiss, R D Wynne, A Marmor. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Critical care medicine. 1989 Sep; 17(9):879-81. doi: 10.1097/00003246-198909000-00006. [PMID: 2766758]
  • H M Lewis, M J Kendall, S R Smith, J R Bratty. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers. British journal of clinical pharmacology. 1989 May; 27(5):547-52. doi: 10.1111/j.1365-2125.1989.tb03416.x. [PMID: 2757879]
  • A Schneeweiss, A Marmor, R D Wynne. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction. Herz. 1988 Aug; 13(4):259-62. doi: NULL. [PMID: 3169679]
  • A J Cowley, R D Wynne, K Stainer, L Fullwood, J M Rowley, J R Hampton. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. BMJ (Clinical research ed.). 1988 Jul; 297(6642):169-73. doi: 10.1136/bmj.297.6642.169. [PMID: 3044507]
  • M F Sim, D B Yates, R Parkinson, M J Cooling. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. British journal of pharmacology. 1988 Jun; 94(2):371-80. doi: 10.1111/j.1476-5381.1988.tb11539.x. [PMID: 3293682]
  • M B Slegowski, C Miller, R S Porter. Simplified high-performance liquid chromatographic determination of flosequinan and its metabolite in plasma, serum and urine. Journal of chromatography. 1988 Mar; 425(1):227-32. doi: 10.1016/0378-4347(88)80026-4. [PMID: 3360874]
  • R D Wynne, E L Crampton, I D Hind. The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers. European journal of clinical pharmacology. 1985; 28(6):659-64. doi: 10.1007/bf00607911. [PMID: 3905414]
  • A J Cowley, R D Wynne, J R Hampton. The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1984 Dec; 2(3):S547-9. doi: NULL. [PMID: 6599715]